1.Cepharanthine alleviates liver injury in a rodent model of limb ischemia-reperfusion.
Chang YK1, Huang SC1, Kao MC2, Huang CJ3. Acta Anaesthesiol Taiwan. 2016 Mar;54(1):11-5. doi: 10.1016/j.aat.2015.11.004. Epub 2015 Dec 19.
OBJECTIVES: Limb ischemia-reperfusion (I/R) causes remote organ injury (e.g., liver injury). Oxidation and inflammation are crucial mechanisms. We investigated the effects of cepharanthine, a potent antioxidative and anti-inflammatory drug, on alleviating liver injury induced by limb I/R.
2.Cepharanthine inhibits in vitro VSMC proliferation and migration and vascular inflammatory responses mediated by RAW264.7.
Paudel KR1, Karki R1, Kim DW2. Toxicol In Vitro. 2016 Mar 25;34:16-25. doi: 10.1016/j.tiv.2016.03.010. [Epub ahead of print]
Pathogenesis of atherosclerosis involves vascular smooth muscle cell (VSMC) migration and proliferation followed by an inflammation mediated by activated macrophages in the tunica intima of blood vessels. Cepharanthine (CEP) belongs to bisbenzylisoquinoline alkaloids found in the plant Stephania cepharantha, which has been used for various diseases like cancer, alopecia areata, venomous snakebites, and malaria. In this study, we investigated whether CEP suppresses VSMC migration and proliferation and inhibits inflammatory mediator production in macrophage (RAW264.7). Our results showed that CEP possessed significant DPPH scavenging and metal chelating activities. It also markedly inhibited lipid peroxidation. Similarly, CEP suppressed the nitric oxide (NO) production and expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) in RAW264.7 cells. Moreover, the level of prostaglandin E2 was also suppressed and the formation of macrophage derived foam cell was attenuated in RAW264.
3.In vitro and in vivo effect of paclitaxel and cepharanthine co-loaded polymeric nanoparticles in gastric cancer.
Yu HH1, Mi WN, Liu B, Zhao HP. J BUON. 2016 Jan-Feb;21(1):125-34.
PURPOSE: Response surface methodology (RSM) using the central composite rotatable design (CCRD) model was used to optimize the formulation of paclitaxel (PTX)-cepharanthine (CEP) nanoparticles for gastric cancer.
4.Cepharanthine mitigates lung injury in lower limb ischemia-reperfusion.
Kao MC1, Yang CH2, Chou WC2, Sheu JR3, Huang CJ4. J Surg Res. 2015 Dec;199(2):647-56. doi: 10.1016/j.jss.2015.06.041. Epub 2015 Jun 23.
BACKGROUND: Oxidation and inflammation caused by lower limb ischemia-reperfusion (I/R) readily induce lung injury. We elucidated whether cepharanthine, a potent antioxidative and anti-inflammatory drug, can mitigate lung injury induced by lower limb I/R. Role of heme oxygenase 1 (HO-1) was also investigated.